anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a red sage root acne-removing repairing cream. For extraction of a red sage root extract, ethanol with concentrations of 90% and 15% is employed; extraction temperature is 65 DEG C; extraction time is 40 min; the dose (a mass-to-volume ratio) of an extraction solvent for extraction is 1: 10 each time; and extraction is carried out three times. The extracted optimal effective parts of red sage root are a 90% ethanol red sage root extract and a 15% ethanol red sage root extract, and the mean values of the anti-propionibacterium acne activity of the two extracts are 16.7 +/- 0.4 mm and 16.7 +/- 0.5 mm, respectively. The mean value of the activity of a mixture composed of the two extracts in a mass ratio of 5: 2 is increased to 18.9 +/- 0.3 mm. The mixture can be used as an acne-removing effective part of red sage root, and the material basis of the mixture are tanshinone and salvianolic acid. The red sage root acne-removing repairing cream is prepared from the mixture and other materials in proportion. The red sage root acne-removing repairing cream prepared in the invention is a natural excellent health care product for the skin, has substantial efficacy, does not result in allergy or other adverse reaction and is good news for patients with acne.
FIELD: chemistry. ^ SUBSTANCE: invention refers to sulphated oligosaccharides of the general formula X-[Y]n-Z-UR1, where X, Y and Z each are the same hexose monosaccharide fragment selected out of group including glucose, mannose, altrose, allose, talose, galactose, idose and gulose, adjoining monosaccharide fragments are bound in 1åÆ2, 1åÆ3, 1åÆ4, and/or 1åÆ6 pattern by glycoside bonds, and each carbon atom not binding X, Y and Z groups is bound by single bond with UR group, with exception for carbon atom in 1 position of Z monosaccharide, to which UR1 group is bound by single bond; where n is an integer within 0 to 6; U is O atom or NH; each R is independently C2-C6-alkenyl, benzyl, SO3M or H, where M is any pharmaceutically acceptable cation of alkali metal or organic amine, or R form N3 together with U; R1 is C1-C12alkyl, benzyl, PEG monomethyl ether or its derivative, C1-C12alkylazide, , or , in the form of ester, free acid, free base or hydrate. Also invention refers to pharmaceutical or veterinary composition based on claimed compounds, for disorder prevention or treatment for mammals in case of proliferate retinopathy, solid tumour and/or metastasis result, coagulation/thrombosis and/or virus infection of organism. Additionally invention refers to application of claimed compounds in medicine production for disorder prevention or treatment for mammals in case of proliferate retinopathy, solid tumour and/or metastasis result, coagulation/thrombosis and/or virus infection of organism. ^ EFFECT: increased efficiency of compound application in medicine. ^ 11 cl, 3 tbl, 1 dwg, 16 ex
PURPOSE: To obtain a hybridoma capable of producing an antibody to a group of three kinds of closely related cytoplasmic antigens of Candida albicans and useful for immunodiagnosis of candidiasis. CONSTITUTION: Biologically pure non-cell-wall cytoplasmic antigens of C. albicans, which are detectable in humans during disseminated candidiasis but not during non-invasive C. albicans infections, and have apparent molecular weights of about 48-52 Kd in sodium dodecylsulfate-polyacrylamide get electrophoresis (SDS-PAGE). The antigens specifically react to a monoclonal antibody produced by a hybridoma selected from a group of hybridomas of ATCC-No. HB-8397 and ATCC-No. HB-8398. Further, the antigens can be obtained by fractionating a mannan-removed cytoplasmic extract of yeast or mycelia of a fungus by ion-exchange chromatography and subsequently subjecting the obtained fractions to get electrophoresis separation.
The present disclosure relates to nitrone azine crystal form, a preparation method, and an application thereof. Provided is a crystal form A of nitrone azine. The 2? position XRPD pattern thereof exhibits characteristic diffraction peaks at 0.60±0.2, 11.03±0.2, 15.31±0.2, 15.55±0.2, 17.14±0.2, 17.93±0.2, 23.81±0.2. The crystal form A has a low risk of crystal transformation and excellent stability, is conducive to the stability of the preparation during preparing and storage process thereof, and effectively guarantees the consistency of the content of the crystal form in the preparation. The crystal form A is also safe, effective, and quality controllable, has higher biological activity and excellent druggability, high bioavailability, rapid drug effect, and high biological activity.
A system and a method for scheduling health examination stations are provided. The system includes an appointment registration module, an examination item comparing module, a historical time recording module, and a health examination scheduling module. The appointment registration module receives appointment examination item information of customers. The examination item comparing module outputs an examination item list according to the appointment examination item information. The historical time recording module obtains a history examination time a historical waiting time which correspond to the examination item list as a time reference information. The health examination scheduling module calculates a waiting and examination time ratio corresponding to the examination item list according to the time reference information, and determines a rest time of the customer to stay at the health examination station after health examination is performed and a waiting time for waiting for health examination at the next health examination station.
The patients will be treated with a standard of care where the treatment will not be controlled, and these patients will act as external control representing clinical practice. However, these patients will be discussed in the head and neck multispeciality clinic and follow the institutional approach. They will be subjected to treatment similar to 'arm 2' but are allowed protocol deviation as per treating radiation oncology discretion.
Each vial of tigecycline for injection should be reconstituted with 5.3 mL of 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP, or Lactated Ringer’s Injection, USP to achieve a concentration of 10 mg/mL of tigecycline. (Note: Each vial contains a 6% overage. Thus, 5 mL of reconstituted solution is equivalent to 50 mg of the drug.) The vial should be gently swirled until the drug dissolves. Reconstituted solution must be transferred and further diluted for intravenous infusion. Withdraw 5 mL of the reconstituted solution from the vial and add to a 100 mL intravenous bag for infusion (for a 100 mg dose, reconstitute two vials; for a 50 mg dose, reconstitute one vial). The maximum concentration in the intravenous bag should be 1 mg/mL. The reconstituted solution should be yellow to orange in color; if not, the solution should be discarded. Parenteral drug products should be inspected visually for particulate matter and discoloration (e.g., green or black) prior to administration. Once reconstituted, tigecycline for injection may be stored at room temperature (not to exceed 25ºC/77ºF) for up to 24 hours (up to 6 hours in the vial and the remaining time in the intravenous bag). If the storage conditions exceed 25ºC (77ºF) after reconstitution, tigecycline should be used immediately. Alternatively, tigecycline for injection mixed with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP may be stored refrigerated at 2° to 8°C (36° to 46°F) for up to 48 hours following immediate transfer of the reconstituted solution into the intravenous bag.  


Tigecycline for injection may be administered intravenously through a dedicated line or through a Y-site. If the same intravenous line is used for sequential infusion of several drugs, the line should be flushed before and after infusion of tigecycline with 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP or Lactated Ringer’s Injection, USP. Injection should be made with an infusion solution compatible with tigecycline and with any other drug(s) administered via this common line.
The aim of this study is to evaluate the effects of oral administration of carbohydrate-electrolyte-containing fluid, compared to standard clear fluid during preoperative fasting on metabolic responses, preoperative anxiety and postoperative complications in paediatric patients. Metabolic responses will be assessed through the degree of insulin resistance (using the Homeostatic Model Assessment for Insulin Resistance - HOMA-IR) and inflammatory cytokine (Interleukin-6) level. The metabolic responses will be evaluated after the induction of anaesthesia and 24 hours following the surgery. Preoperative anxiety will be assessed before the surgery using the Modified Yale Preoperative Anxiety Scale Short Form (mYPAS-SF). Immediate post operative complications such as post operative nausea and vomiting (PONV), emergence delirium and postoperative pain will be assessed in the recovery room. This study is a single-blinded randomised controlled trial. Subjects will be randomly allocated into 2 groups: the intervention group will receive carbohydrate-electrolyte fluid whereas the control group will receive clear fluid. Both groups will receive 50 ml/kg of their designated fluid one day prior to surgery, and are allowed to consume the fluid gradually since the fluid is given (approximately 12 hours before the surgery) until 1 hour before induction of anaesthesia. The fluid used in this study will be prepared by the Pharmacy Department, independent from the research team, in which the randomization and which fluid given to patients remain concealed from the primary research team.
Patients undergo laparotomy within 6 weeks after last cycle of standard of care neoadjuvant chemotherapy. Within 6 weeks after surgery, patients receive standard of care chemotherapy.
The present invention relates to a Chinese medicine for treating osteological diseases and a preparation method. The present invention using antlers, longspur epimedium, roucongrong, eucommia bark and prepared rehmannia roots as main materials has the functions of invigorating kidneys, replenishing essence, replenishing marrow and strengthening bones and muscles. The present invention combined with all medicines has the efficiency of invigorating kidneys, promoting Yang, activating blood circulation, relieving pain, dispelling wind damp and clearing away wetness. The microcirculation of a body organization is obviously improved by the therapy of the present invention, the blood flow of the body organization is increased, the metabolism of organic matter, calcium and phosphorus is regulated, nutrient supply to bone joints is increased, and the metabolism activity of bone cells, the abrasion resistance and the impact resistance loading force of soft joint tissues are enhanced. The present invention carries out 354 medical cases through clinical observation in Heilongjiang Hospital and Shangzhi Hospital of Chinese Medicine, wherein the cases comprise 54 cases of femoral head necrosis, 200 cases of lumbar disc protrusion, and 100 cases of rheumatism and rheumatoid diseases; all diseases are determined by symptoms, signs, testing, X rays or CT examination. Via clinical statistic, the present invention has the total effective rate of 97.6% and the curing rate of 80% without any side effect.
Transplantation of unrelated cord blood units is done at least 24 hours after last chemotherapy and carried out during the same day. The unit presenting the best degree of HLA compatibility with the patient will be transfused in first. If the 2 units have the same degree of HLA compatibility with the recipient, the unit with the higher cell dose will be transfused in first. A 2 hours time interval between the 2 transfusions will be respected.
The present disclosure relates to a two-component hair care agent comprising a first component and a second component, the first component and the second component being provided separately from one another, the first component or the second component containing a colour indicator which shows a colour change (halochromic) in a pH-value range from 3-6, the first component having a pH value in a range from 2-4, and the second component having a pH value in a range of greater than 4-9. Mixing the components may result in a pH from 3-6. The components may be hydrophilic, lipophilic or an emulsion. The composition may be free of oxidizing agents, substantive dye, oxidation dye precursor. The colour indicator may be methyl orange, methyl red, resorcinol yellow, quinaldine red, Congo red, bromocresol green, bromothymol blue, and may be present from 0.000001-0.1 wt%. The two components may be provided in a ratio form 1:10 to 10:1. The mixture may be applied to keratinic fibres (keratin, hair), and may be exposed to water and/or rinsing with water.
The present disclosure relates to use of a  Clostridium ghonii  spore combined with pembrolizumab in cancer treatment. It is found for the first time that the  Clostridium ghonii  spore combined with pembrolizumab can significantly improve a curative effect of colon cancer and reduce a dose of the pembrolizumab, and thus is efficient and low-toxic. Oncolysis by  Clostridium ghonii  can affect immunogenicity of a tumor microenvironment (TME) by various ways, converts an immunosuppressive state of the TME into an immune-activated state, adjusts the immunosuppressive TME, and breaks an immune tolerance. An optimal combination of the  Clostridium ghonii  spore and the pembrolizumab thoroughly removes about 20% of mouse tumor tissues. A benefit range of patients with tumors treated by a PD-1 antibody is expanded. The combination even has an obvious curative effect on patients failed the treatment by the PD-1 antibody.
During neurosurgical procedures intubation, insertion of the head pins, extubation and the early postoperative period are the time lines in which cerebral autoregulation can be impaired by changes in heart rate and blood pressure. Several anesthetic regimens have been implied to overcome this problem. Remifentanil is used in neurosurgery since it allows early recovery and neurologic evaluation. Esmolol on the other hand is also very short acting, effective to blunt cardiovascular responses during surgery and has no significant effect on intracranial pressure and cerebral blood flow. In addition esmolol is addressed to reduce perioperative ischemia during noncardiac surgery.

It was hypothesized that the use of esmolol as an alternative to remifentanil with sevoflurane inhalation anesthesia during intracranial surgery, could provide better hemodynamic conditions and cause lesser side effects in the perioperative period. It was the main objective of this study to compare the effect of esmolol and remifentanil on the incidence of tachycardia and hypertension and the intraoperative fentanyl consumption. The comparison of postoperative troponine I and creatine phosphokinase levels and EKG changes were the secondary objectives.
The proposed project is a 1-year pilot program of research, which will examine the feasibility of a new, intramuscular (IM) long-acting form of naltrexone. The long-acting form of naltrexone may improve medication adherence, which has been shown to be critical to successful naltrexone treatment of alcohol dependence. The study is a 16-week, randomized, prospective, open-label trial, including a 12-week course of monthly naltrexone injections. A follow-up interview will be conducted 4 weeks after discontinuation of medication. Thirty subjects will be recruited. Voucher-based incentives will be provided to all subjects to ensure attendance for medication administration. Weekly motivational counseling sessions will be conducted and will focus on improving motivation to stop alcohol use. Study outcomes consist of self-report and biological measures of alcohol use; measures of psychiatric symptom severity and neurocognitive functioning; and genetic testing to examine functional polymorphism (Asn40Asp) differences in the subjects' μ-opioid receptors (OPRM1), which may predict response to naltrexone treatment.
GW870086X is a potent glucocorticoid agonist in human in vitro functional assays that is under development as an inhaled treatment for asthma in children. This study will determine the PK characteristics and assess the safety and tolerability of the nebules formulation of GW870086X in healthy volunteers after 14 days of dosing.

This is the first clinical study that will be assessing the nebules formulation. The purpose of this study is to ensure that the doses that have been selected have a good safety profile in line with what has been found in the previous DPI formulation studies, and to assess the PK profile after single (Day 1) and repeat dose (Day 14) to select appropriate doses for future studies with the nebules formulation. This study will also provide additional safety cover with the nebules formulation given over a longer duration than studied previously with the DPI formulation before moving into the paediatric programme. This study is designed to give at least 5-fold cover for the highest dose to be studied in future paediatric programmes. During this study cortisol production will be assessed by measuring 24 hour cortisol profile in serum and urine as well as performing an ACTH stimulation test. Two doses (5mg and 8.75mg) have been selected. These doses are 5 and 10 times higher than the anticipated maximum clinical dose. The doses have been selected to ensure sufficient safety cover in future paediatric studies as well as to confirm the absence of significant adrenal inhibition at doses that would be expected to cause complete inhibition of cortisol production with traditional steroids.
Anterior cruciate ligament (ACL) reconstruction is the 6th most common orthopaedic procedure. Disruption of the ACL leads to altered knee function and significantly increases the risk for osteoarthritis (OA). Current methods to reconstruct the ACL are generally perceived to be successful; however, several recent meta-analyses have indicated that normal structure and function of the knee is restored only 60% to 70% of the time and 60 to 90% have radiographic evidence of knee OA within 10 to 20 years. Though the causes of post-traumatic OA are almost certainly multifactorial, a significant factor contributing to the increased risk for OA following ACL injury and surgery may be failure to restore normal anatomy and kinematics of the knee.

We have previously shown that conventional single-bundle (SB) ACL reconstruction fails to restore normal knee kinematics, leading to altered patterns of joint loading. There is growing support for the theory that cartilage adapts to its local loading environment and abnormal joint loading may play an important role in the development and progression of OA. Our understanding of ACL anatomy has also improved over the last few years, revealing the shortcomings of current surgical techniques to restore anatomy of the ACL. We have developed double-bundle (DB) surgical procedures to restore normal anatomy of the anteromedial (AM) and posterolateral (PL) bundles of the ACL. The underlying principle for this approach is that more anatomical graft placement will lead to better knee mechanics, which are necessary for improved long-term outcome.

To determine if anatomic DB ACL reconstruction can effectively restore normal dynamic knee function, we will conduct a double-blind randomized clinical trial to compare SB vs. anatomic DB ACL reconstruction. The specific aims of this study are to determine if DB is better than SB ACL reconstruction in terms of 1) dynamic knee function and 2) clinical outcomes. We will randomly assign 160 subjects with an isolated ACL injury to SB or DB ACL reconstruction and will follow the subjects for 2 years. We will utilize a unique combination of high-speed biplane radiography (for accurate assessment of knee kinematics) and 3D imaging (MRI and CT, to define joint and cartilage morphology) to characterize joint kinematics and cartilage surface interactions during functional tasks. Clinical outcomes will include laxity, range of motion, functional strength and patient-reported symptoms, function and activity. Successful completion of this study will provide evidence of the efficacy of anatomic DB ACL reconstruction for restoring normal knee mechanics and improving clinical outcomes. If the results show a clear benefit of this procedure, then a sound basis will have been established for future studies to assess the benefits of anatomic DB ACL reconstruction on long-term clinical outcomes and joint health.
People are routinely forced to undertake cognitive challenges under the effect of sleep deprivation, due to professional and social obligations forcing them to ignore their circadian clock. However, low intra-individual and high inter-individual differences in behavioural outcomes are known to occur when people are sleep deprived, leading to the conclusion that trait-like differences to sleep deprivation could explain the differing levels of resilience. Within this study we consider if trait-like resilience to sleep deprivation, measured using psychomotor vigilance tests over a 40 h protocol, could be associated with graph metrics (mean node strength, clustering coefficient, characteristic path length and stability) calculated from EEG functional networks acquired when participants ([Formula: see text]) are well rested (baseline). Furthermore, we investigated how stability (the consistency of a participant's functional network over time measured using 2-D correlation) changed over the constant routine. We showed evidence of strong significant correlations between high mean node strength, low characteristic path length and high stability at baseline with a general resilience to extended sleep deprivation, although the same features lead to vulnerability during the period of natural sleep onset, highlighting non-uniform correlations over time. We also show significant differences in the levels of stability between resilient and vulnerable groups.
Disclosed herein are methods of improving skin appearance associated with skin aging. The method comprises the step of applying an anti-aging bioactive composition to a skin surface having at least one sign of aging. The anti-aging bioactive composition is applied for a period of time sufficient to improve the appearance of the at least one sign of aging. In one embodiment, the anti-aging bioactive composition comprises an effective amount of a Nelumbo nucifera (Sacred Lotus) serum fraction. In another embodiment, the anti-aging bioactive composition comprises an effective amount of a Chamomilla recutita (German Chamomile) Flower serum fraction. In other embodiments, the anti-aging bioactive composition can further include a dermatologically acceptable carrier.
Measurement of intraocular pressure (IOP) with iCare ST500 compared to GAT and iCare IC200. Measurements will be performed in three categories: Low IOP (7 to 16 mmHg), Medium IOP (\>16 to \<23 mmHg), or High IOP (≥23 mmHg).